Citigroup Maintains Neutral on Merck & Co, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Neutral 52.1%

Neg 0% Neu 52.1% Pos 0%

Citigroup analyst Geoff Meacham maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $120 to $125.